West Pharmaceutical Services WST Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from West Pharmaceutical Services’s reported figures.
Based on the most recent quarter.
The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about West Pharmaceutical Services's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is West Pharmaceutical Services's net debt / EBITDA?
- West Pharmaceutical Services (WST) reported net debt / EBITDA of -0.2× in Q1 2026.
- How has West Pharmaceutical Services's net debt / EBITDA changed year-over-year?
- West Pharmaceutical Services's net debt / EBITDA decreased by 77.6% year-over-year, from -0.1× to -0.2×.
- What is the long-term trend for West Pharmaceutical Services's net debt / EBITDA?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's net debt / EBITDA has grown at a -2.3% compound annual growth rate (CAGR), from -1.6× to -1.5×.
- What does net debt / EBITDA mean?
- How many years of operating earnings it would take to pay off the company's net debt.
- How do you interpret net debt / EBITDA?
- Lower is safer; lenders often covenant around 3–4×. A negative value means net cash (more cash than debt), a position of strength. Spikes can reflect a temporary EBITDA dip rather than new borrowing.
- How does net debt / EBITDA compare across companies?
- A standard leverage yardstick across non-financial sectors; covenant thresholds vary by industry cash-flow stability.